Tumor Lysis Syndrome.

Area of Science:

• Oncology
• Nephrology
• Critical Care Medicine

Background:

• Tumor lysis syndrome (TLS) is a life-threatening oncologic emergency.
• Characterized by rapid tumor cell breakdown, leading to severe electrolyte imbalances (hyperkalemia, hyperuricemia, hyperphosphatemia, hypocalcemia).
• Associated with significant risks including acute kidney injury (AKI), cardiac arrhythmias, seizures, and mortality.

Purpose of the Study:

• To summarize the pathophysiology, clinical manifestations, and management strategies for tumor lysis syndrome.
• To emphasize the importance of early recognition and preventative measures in at-risk patients.

Main Methods:

• Review of existing literature on tumor lysis syndrome.
• Analysis of clinical guidelines and case reports regarding TLS management.
• Discussion of pharmacological interventions and supportive care.

Main Results:

• TLS necessitates prompt management including hydration and electrolyte correction.
• Uric acid-lowering agents like rasburicase and allopurinol are crucial.
• Prophylactic measures, including aggressive intravenous hydration and preemptive medication, are vital for preventing TLS.

Conclusions:

• Early identification and intervention are critical for improving outcomes in TLS.
• Preventative strategies are paramount in mitigating the severe complications of tumor lysis syndrome.
• Multidisciplinary care is essential for managing this oncologic emergency.